Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
25%
Ph not_applicable
5
63%
Ph phase_2
1
13%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
2(25.0%)
N/ANon-phased studies
5(62.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(7)
Other(1)

Detailed Status

Completed7
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (12.5%)
Phase 32 (25.0%)
N/A5 (62.5%)

Trials by Status

completed788%
unknown113%

Recent Activity

0 active trials
Showing 5 of 8
unknownphase_3

Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma

NCT00460681
completednot_applicable

Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients

NCT00002049
completedphase_3

Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy

NCT00002109
completednot_applicable

Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection

NCT00002051
completednot_applicable

A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients

NCT00002050
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT00460681Phase 3

Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma

Unknown
NCT00002049Not Applicable

Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients

Completed
NCT00002109Phase 3

Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy

Completed
NCT00002051Not Applicable

Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection

Completed
NCT00002050Not Applicable

A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients

Completed
NCT00002289Not Applicable

The Effects of Thymopentin on HIV Infectivity of Blood Cells and Semen in HIV-Infected Patients

Completed
NCT00002332Phase 2

A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs

Completed
NCT00002066Not Applicable

Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8